Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP / 生物医学工程学杂志
Journal of Biomedical Engineering
; (6): 300-323, 2002.
Article
de Zh
| WPRIM
| ID: wpr-263604
Bibliothèque responsable:
WPRO
ABSTRACT
The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Médronate de technétium (99mTc)
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Ophtalmopathie basedowienne
/
Immunosuppresseurs
Type d'étude:
Clinical_trials
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Biomedical Engineering
Année:
2002
Type:
Article